atorvastatin has been researched along with Cardiomyopathy, Hypertrophic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, L; Liu, X; Mu, S; Sui, M; Xie, R; Yu, C; Zhao, S; Zou, C | 1 |
| Lombardi, R; Marian, AJ; Nagueh, SF; Tan, Y; Wang, J; Willerson, JT | 1 |
| Kostner, KM | 1 |
| Davidson, SM; Elliot, PM; Harding, SE; Hausenloy, DJ; McGregor, C; Rees, PS; Yellon, DM | 1 |
| Chen, SN; Halder, T; Marian, AJ; Nagueh, SF; Roberts, R; Senthil, V; Tsybouleva, N; Willerson, JT | 1 |
| Angermann, CE; Bauersachs, J; Ertl, G; Fidler, F; Frantz, S; Hoyer, C; Kung, M; Störk, S; Waller, C; Weidemann, F | 1 |
1 trial(s) available for atorvastatin and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Cardiomyopathy, Hypertrophic; Cholesterol, LDL; Double-Blind Method; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Pyrroles; Ventricular Dysfunction, Left | 2007 |
5 other study(ies) available for atorvastatin and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling.
Topics: Animals; Atorvastatin; Blotting, Western; Cardiomyopathy, Hypertrophic; Cell Size; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Myocytes, Cardiac; Parathyroid Hormone; Rats; Rats, Wistar | 2016 |
Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiomegaly; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Male; Middle Aged; Pilot Projects; Pyrroles; Statistics as Topic; Treatment Outcome; Young Adult | 2010 |
Statin therapy for hypertrophic cardiomyopathy: too good to be true?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anticholesteremic Agents; Atorvastatin; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2010 |
The mitochondrial permeability transition pore as a target for cardioprotection in hypertrophic cardiomyopathy.
Topics: Atorvastatin; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cells, Cultured; Cyclosporine; Heptanoic Acids; Humans; Ion Channel Gating; Membrane Potential, Mitochondrial; Microscopy, Confocal; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Reperfusion Injury; Myocytes, Cardiac; Pyrroles; Time Factors | 2013 |
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Atorvastatin; Cardiomyopathy, Hypertrophic; Cholesterol; Disease Models, Animal; DNA, Mitochondrial; Extracellular Signal-Regulated MAP Kinases; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Myosin Heavy Chains; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyrroles; Rabbits; Ventricular Function, Left | 2005 |